The latest biotech news

News and Trends 2 Sep 2015

Alexion launches a duo of new therapies for ultra-rare diseases in the EU

Thanks to Alexion Pharmaceuticals, two ultra-rare diseases finally got the first treatment in the European Union, namely Lysosomal acid lipase deficiency (LAL-D) and Pediatric-onset hypophosphatasia. Alexion ramps up its product-pipeline. Until now, the Connecticut-based company, which comprises a market cap of about $38.5Bn (€34,2Bn), has lived mostly on sales of Soliris, the most expensive drug on […]

September 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Sep 2015

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Paris based Sanofi has pulled out of a €176M deal with Californian clinical stage biotech Ardelyx. A licensing deal for a program of pre-clinical candidates treating renal diseases and IBS-C, similar to Tenapanor, was revoked. In February 2015, Fresno County’s Ardelyx announced its pharma-baby, Tenapanor, had passed its stage IIB clinical trials in successfully reducing serum levels of phosphate. […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Carmat’s Artificial Heart is now inside three patients – how’s it doing?

So preliminary trial results look good – it could be that the next phase will go forward too. The artificial heart of French pioneer Carmat shows several device failures but overcomes major side effects of former gadgets, such as thromboembolism or haemorrhage. Heart failure is the world’s leading cause of death. In Europe alone, 15 million patients […]

September 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Sep 2015

Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant

Novo Nordisk has acquired two small Indiana based research Biotechs, Calibrium and MB2, as part of its strategy to establish itself in the US as a major Diabetes research giant. Novo Nordisk, a global endocrine research giant hailing from Copenhagen, Denmark, has plans to acquire two smaller, privately held research companies into its conglomeration. Focusing […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 1 Sep 2015

Does your business plan need some enhancement? The Science4Life Venture Cup 2016 kicks off today!

The application for Germany’s Science4Life Venture Cup 2016 is now open! Join the competition to meet sector-specific experts, benefit from the experiences of former participants and win up to €25k to help your startup to get to the next level. Labiotech knows from its own experience that an aspiring startup needs a convincing business plan […]

September 1, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 1 Sep 2015

Genentech’s Sean Bohen defects to AstraZeneca as CMO

AstraZeneca‘s Senior management team gets reinforced by Sean Bohen, a top executive from Roche‘s subsidiary Genentech. Starting in two weeks, he will push late-stage treatments to the market. It’s been two months since two senior manager left the struggling AstraZeneca. Among them, Briggs Morrison, who left to become new CEO of Syndax. To replace him, […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Sep 2015

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

A new research competition is born. The European Society of Cardiology and Boehringer Ingelheim will award €400k to four research projects treating cardiovascular diseases. Big Pharmas like to give a push to aspiring research projects within their field. GSK is a key partner of the world’s largest life science startup accelerator, namely OneStart. Sanofi is engaged […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 31 Aug 2015

When Tech and Biotech merge, Google and Sanofi partner up to revolutionize Diabetes Management

Taking care of diabetes is still far too complex currently. In future, Sanofi and Google will jointly take care of this problem, hoping to ease the life of millions of people with type 1 and type 2 diabetes. When it comes to transforming our diabetes treatment technology, Google loves European Pharmas. Together with Novartis, it […]

August 31, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 31 Aug 2015

Review: The Future of Biomarkers in Immuno-Oncology

Immuno-oncology is a Biotech field that is more than just hype – it could solve one of humanity’s biggest health challenges: Cancer. In order to bring more effective treatments with fewer side-effects, Biomarkers will play a key role. I wanted to get an expert view on the subject, so I called Bernhard Sixt, CEO of the […]

August 31, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 29 Aug 2015

Cambridge’s Algal Innovation Center is soon finished!

The European Energetic Algae project explores the potential of algae as an energy source. Its half a million euros Algal Innovation Center in Cambridge will soon scale up the research. The Energetic Algae project, shortly EnAlgae, aims to reduce our reliance on fossil fuels by developing biofuel technologies based on algae. “A lot of people don’t realize […]

August 29, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 28 Aug 2015

[Update] Valneva’s duck stem cells attract two new Vaccine-deals

French Valneva continues to sign license agreements for its duck derived stem cell line that produces novel vaccines. Lyon-based Valneva was formed from the 70-year old duck breeder Group Grimaud. It entered the biotech scene in 2000 as Vivalis and today is on Euronext-Paris and the Vienna stock exchange, has a market cap of about €275M […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 28 Aug 2015

FDA shelves UniQure’s Glybera – will the Gene therapy once reach the US market?

The €1.1M drug Glybera was the first gene therapy on the European market. UniQure wants to sell it in the US too, but the FDA makes it much more difficult than expected. UniQure’s financial report of the first half of 2015 shows good results, cash and cash equivalents of the company increased to €181.9M, compared with […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Alexion launches a duo of new therapies for ultra-rare diseases in the EU

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Carmat’s Artificial Heart is now inside three patients – how’s it doing?

Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant

Does your business plan need some enhancement? The Science4Life Venture Cup 2016 kicks off today!

Genentech’s Sean Bohen defects to AstraZeneca as CMO

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

When Tech and Biotech merge, Google and Sanofi partner up to revolutionize Diabetes Management

Review: The Future of Biomarkers in Immuno-Oncology

Cambridge’s Algal Innovation Center is soon finished!

[Update] Valneva’s duck stem cells attract two new Vaccine-deals

FDA shelves UniQure’s Glybera – will the Gene therapy once reach the US market?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!